| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2023 | TREKKA THERAPEUTICS, LLC | 3218 RED OAK DR | SAINT PAUL | MN | 55121-2336 | DAKOTA | USA | R41CA278184 | A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer Platform | 000 | 1 | NIH | 6/18/2025 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $547,802 ) |
| | 2023 | 2023 | TREKKA THERAPEUTICS, LLC | 3218 RED OAK DR | SAINT PAUL | MN | 55121-2336 | DAKOTA | USA | R41CA278184 | A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer Platform | 001 | 1 | NIH | 9/19/2023 | $147,823 |
| | 2023 | 2023 | TREKKA THERAPEUTICS, LLC | 3218 RED OAK DR | SAINT PAUL | MN | 55121-2336 | DAKOTA | USA | R41CA278184 | A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer Platform | 002 | 1 | NIH | 9/21/2023 | -$399,979 |
| | 2023 | 2023 | TREKKA THERAPEUTICS, LLC | 3218 RED OAK DR | SAINT PAUL | MN | 55121-2336 | DAKOTA | USA | R41CA278184 | A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer Platform | 002 | 1 | NIH | 9/21/2023 | $399,979 |
| | 2023 | 2023 | TREKKA THERAPEUTICS, LLC | 3218 RED OAK DR | SAINT PAUL | MN | 55121-2336 | DAKOTA | USA | R41CA278184 | A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer Platform | 000 | 1 | NIH | 2/28/2023 | $399,979 |
|
|
